A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo

Cited by papers we hold 17

• Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation · 2023
  No notice
• Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease? From preclinical studies to the clinical trials · 2023
  No notice
• The Pivotal Role of NF-kB in the Pathogenesis and Therapeutics of Alzheimer’s Disease · 2022
  No notice
• “Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies · 2021
  No notice
• GSK-3 and Tau: A Key Duet in Alzheimer’s Disease · 2021
  No notice
• Tau strains shape disease · 2021
  No notice
• GSK3β and Tau Protein in Alzheimer’s Disease and Epilepsy · 2020
  No notice
• An Overview on the Clinical Development of Tau-Based Therapeutics · 2018
  No notice
• Advances in developing novel therapeutic strategies for Alzheimer’s disease · 2018
  No notice
• Roles of tau protein in health and disease · 2017
  No notice
• The roles of lipid and glucose metabolism in modulation of β-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease · 2015
  No notice
• PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia · 2015
  No notice
• GSK-3β, a pivotal kinase in Alzheimer disease · 2014
  No notice
• The Importance of Tau Phosphorylation for Neurodegenerative Diseases · 2013
  No notice
• Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review · 2012
  No notice
• Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease · 2012
  No notice
• LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice · 2010
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.